Dominic Piscitelli

This week we presented promising preclinical data highlighting ORIC-944, our potent and selective allosteric inhibitor of PRC2, as well as our novel PLK4 discovery program at #AACR2023. Learn more about preclinical data presented here: bit.ly/41DnbU5

Our Chief Scientific Officer Lori Friedman, PhD, has spent more than 20 years advancing discovery research to better the lives of patients with cancer. Today we are proud to congratulate her on being elected as @AACR CICR Working Group Chair-Elect. bit.ly/3M3oiYw

It’s been an exciting year for ORIC! As we bring this year to a close, we are thankful for all that we’ve accomplished and look forward to an exciting 2023. #HappyNewYear

The ORIC team had a great time at #AACR22. After two years of only virtual meetings, it nice to present our science, learn and socialize in-person! Looking forward to next year.

At ORIC, everyday is #EmployeeAppreciationDay. That’s why we foster a collaborative, empowering culture that gives ORIC employees the responsibility and support to do groundbreaking work that directly improves the lives of patients.

At ORIC, we know the value of advancing #DiversityinScience having women represent 55% of our leadership team and 49% of our overall team. Today’s girls in #STEM are tomorrow’s scientists. Let’s continue to empower women & girls in science. #IDWGS #womeninscience #girlinscience

We are thrilled to announce regulatory clearance of our CTA for ORIC-114. Read the full press release here: bit.ly/3GW7v4i

President and CEO @JacobChackoMD will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30th at 10:00 a.m. ET. Watch the live or archived chat here: bit.ly/3jDTfUP

September is #ProstateCancerAwarenessMonth. At ORIC, we are committed to our work to Overcome Resistance In Cancer, including #ProstateCancer, with our potent and selective glucocorticoid receptor antagonist ORIC-101. Join us in bringing awareness to this deadly disease.

We’re searching for truth-seeking, curious, patient-centered individuals across various roles. If you want to make an impact on the lives of people with cancer, learn more about our #openroles here: bit.ly/3gRbfJG #Hiring #JoinUs #careers #PharmaJobs

From all of us at ORIC, wishing everyone a happy, safe and fun Fourth of July! #IndependenceDay #4thofJuly

Lori Friedman, $ORIC CSO, will be giving a talk at the Virtual @KeystoneSymp focused on #PrecisionOncology. Learn more or register for the event here: bit.ly/3eq1Nfh #VKSPrecisionOnco21

It’s #NationalCancerResearchMonth and we’d like to take a moment to recognize the brave patients battling cancer and our team & many others out there dedicating their lives to developing innovative cancer therapies in the hopes of finding a cure. #ResearchSavesLives #NCRM21

ORIC presented posters on four programs today at the 2021 AACR Annual meeting. Each poster is available for viewing on the ORIC website here, bit.ly/3dM4aHK.

ORIC-114 is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. The AACR poster can be found on the ORIC website, bit.ly/3dXGYqe

Excited to see ORIC co-founder Charles Sawyers, M.D. honored with AACR’s Distinguished Public Service Award, for his work establishing the GENIE data sharing consortium to address challenges in precision oncology, during the AACR Annual Meeting 2021 Opening Ceremony! #AACR2021

Like many, we are disturbed, dismayed, and saddened by the escalating violence against Asian Americans. At ORIC, we stand up for one another and we stand up for everyone in our society. #StopAsianHate #StopAAPIHate

It’s #EmployeeAppreciationDay and we’d like to take a moment to recognize our entire staff, especially our employees who’ve been coming into the office throughout shelter in place. They’ve enabled us to continue our work during the pandemic.